Arcedi Biotech

Executive Summary

Arcedi Biotech is a Danish diagnostics company revolutionizing prenatal testing. Their proprietary technology isolates intact fetal cells from a routine maternal blood sample, enabling genome-wide comprehensive genetic analysis. This approach overcomes the limitations of current methods: invasive procedures like amniocentesis carry risk, while cell-free DNA (cfDNA) testing provides only limited information. The company's flagship product, EVITA TEST COMPLETE, offers a non-invasive, safe, and complete prenatal screening solution, potentially replacing both invasive tests and cfDNA. The technology holds promise for detecting a wider range of genetic conditions with higher accuracy. Arcedi is positioned to capture a significant share of the global prenatal diagnostics market. With a strong IP portfolio and strategic partnerships, the company is advancing toward commercialization. Validation studies and regulatory approvals are key near-term milestones. The management team's expertise in diagnostics and reproductive health underpins execution capability. Arcedi's disruptive approach could transform standard of care, but regulatory hurdles and competitive landscape remain challenges. The company's progress over the next 12-18 months will be critical.

Upcoming Catalysts (preview)

• Q3 2026Completion of pivotal clinical study for EVITA TEST COMPLETE75% success
• Q4 2026Regulatory submission for CE marking or FDA clearance60% success
• Q2 2026Strategic partnership with a major diagnostics company for distribution50% success